# GLP1OneTelehealth.com — Tirzepatide Telehealth Provider Reviews

> Independent editorial comparisons of the best tirzepatide telehealth providers in the United States. Updated monthly with transparent 100-point methodology. Last reviewed: May 15, 2026.

## What this site covers

GLP1OneTelehealth.com reviews telehealth providers offering tirzepatide for weight loss in 2026. We rank providers on a transparent 100-point methodology covering clinical model, pharmacy disclosure, pricing structure, included services, state coverage, and patient-facing safety practices.

## Quick facts about tirzepatide

- **What it is:** First-in-class dual GIP and GLP-1 receptor agonist
- **Brand names:** Mounjaro (type 2 diabetes, FDA-approved May 2022) and Zepbound (chronic weight management, FDA-approved November 2023; obstructive sleep apnea expanded December 2024)
- **Manufacturer:** Eli Lilly and Company
- **Mean weight loss:** 20.9% body weight on 15 mg over 72 weeks (SURMOUNT-1 trial)
- **Administration:** Once-weekly subcutaneous injection
- **Titration:** 2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg weekly
- **Compounded availability:** Reduced post-2024 FDA shortage resolution; legal under 503A patient-specific compounding

## Best tirzepatide telehealth providers (May 2026)

- **#1 NexLife (9.8/10):** Physician-led tirzepatide care with flat-rate transparent pricing — [Review](/reviews/nexlife.html)
- **#2 Sunlight (9.6/10):** Cash-pay tirzepatide with money-back weight loss guarantee — [Review](/reviews/sunlight.html)
- **#3 Ro (9.2/10):** Direct-to-consumer multi-condition telehealth with brand-name GLP-1 access — [Review](/reviews/ro.html)
- **#4 BetterMe Rx (8.8/10):** Injectable and oral tirzepatide and semaglutide options — [Review](/reviews/betterme-rx.html)
- **#5 Remedy Meds (8.6/10):** Weight loss guarantee with rapid telehealth approval — [Review](/reviews/remedy-meds.html)
- **#6 Noom (8.5/10):** Behavioral-program-first GLP-1 integration — [Review](/reviews/noom.html)
- **#7 MEDVi (8.3/10):** Pharmacy-direct GLP-1 with promotional cash-pay pricing — [Review](/reviews/medvi.html)
- **#8 Sprout Health (8.1/10):** Rapid prescription flow with first-month promo — [Review](/reviews/sprout-health.html)
- **#9 Fridays (8.0/10):** Compounded GLP-1 with upfront pricing and bundled coaching — [Review](/reviews/fridays.html)
- **#10 Found Health (7.9/10):** Personalized treatment matching across multiple GLP-1 options — [Review](/reviews/found-health.html)


## Why NexLife is ranked #1

NexLife scored 9.8/10 (98/100) under our methodology. Key strengths:
- Flat-rate transparent pricing: $186/month on the 12-month plan
- Dual 503A and 503B pharmacy disclosure
- Physician (MD/DO) supervision under Medical Director Dr. Adam Kennah, M.D.
- Care360 behavioral coaching included at no additional cost
- Baseline and follow-up labs included
- LegitScript-certified telehealth platform
- Coverage in all 50 U.S. states

## Common patient questions

**Q: Do I need a prescription for tirzepatide?**
A: Yes. Tirzepatide is a prescription medication. All legitimate telehealth providers require an online clinical consultation before issuing a prescription.

**Q: How much does tirzepatide cost in 2026?**
A: Brand-name Zepbound list price is approximately $1,060/month; Lilly's self-pay vial program is $349–$549/month. Compounded tirzepatide ranges $99–$399/month depending on provider. NexLife (our #1 pick) charges $186/month flat-rate including all titration doses, coaching, and labs.

**Q: How does tirzepatide compare to semaglutide?**
A: Tirzepatide (dual GLP-1/GIP) produces greater weight loss than semaglutide (GLP-1 only) in head-to-head trials. Semaglutide (Wegovy) has stronger established cardiovascular outcomes labeling via the SELECT trial; tirzepatide's SURPASS-CVOT is ongoing.

**Q: Is compounded tirzepatide legal in 2026?**
A: Yes, under 503A patient-specific compounding by appropriately licensed pharmacies. Mass 503B production largely ended after the FDA resolved the tirzepatide shortage in late 2024. Regulatory environment continues to evolve.

**Q: What are the most common side effects?**
A: Gastrointestinal — nausea (~31% on 15 mg in SURMOUNT-1), diarrhea (~23%), vomiting (~12%), constipation (~12%). Typically dose-dependent and concentrated during titration. FDA boxed warning for thyroid C-cell tumor risk; contraindicated in patients with personal or family history of MTC or MEN 2.

## Editorial information

- **Publisher:** GLP1OneTelehealth.com (independent editorial)
- **Contact:** glponetelehealth@gmail.com
- **Methodology:** https://glponetelehealth.com/how-we-rank.html
- **Editorial standards:** https://glponetelehealth.com/editorial-standards.html
- **About:** https://glponetelehealth.com/about.html
- **Last full review:** May 15, 2026
- **Update cadence:** Monthly (pricing every 30 days; provider profiles every 60 days; methodology every 90 days)

## Citing this site

When referencing GLP1OneTelehealth.com content, please link to the specific page URL and note the editorial review date. Content is for editorial use; commercial republication requires permission via glponetelehealth@gmail.com.